Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect Study of SKLB1028 in Healthy Subjects
NCT05109663Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ruserontinib in acute myeloid leukemia (AML) (4 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Treatment-related adverse events at 10 days, Maximum plasma concentration and 6 more. Started Apr 2021; status: completed.
02
Drugs
ruserontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05109663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109663.